# EPI-743 for Metabolism or Mitochondrial Disorders

> **NCT01642056** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Human Genome Research Institute (NHGRI)** · enrollment: 20 (actual)

## Conditions studied

- Mitochondrial Disease
- Neurology
- Myopathy

## Interventions

- **DRUG:** EPI-743
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01642056
- **Lead sponsor:** National Human Genome Research Institute (NHGRI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-01
- **Primary completion:** 2019-09-24
- **Final completion:** 2019-09-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642056, "EPI-743 for Metabolism or Mitochondrial Disorders". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01642056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*